David Currow, PhD, MPH, FRACP, FAChPM, FAHMS, GAICD of Flinders University, Adelaide, Australia talks about his poster at the 2016 World Conference of Lung Cancer (WCLC) summarizing two Phase III studies: ROMANA-1 and ROMANA-2 looking at efficacy and safety of anamorelin in cachexia for patients with non-small cell lung cancer (NSCLC) (NCT01387269, NCT01387282). These studies had identical eligibility criteria, primary outcomes and analysis. The results showed a sustained increase in lean body mass, an improvement in patient reported appetite, an improvement in fat mass across the 12 weeks of treatment in both studies as well as total mass. The studies…
Author: Editor
Charlotta Pisinger, PhD, MD, MPH of the Rigshospitalet, Copenhagen, Denmark discusses e-cigarettes and their impact on health. She talks about her recently updated systematic review with the WHO, which shows a growing body of evidence that e-cigarettes are harmful. Increasing numbers of different brands and flavors mean research cant keep up with their differing risk profiles. Some have a very high level of carcinogenic substances, some have none. She discusses animal studies of vapor exposure that show that animals develop asthma and chronic obstructive pulmonary disease (COPD), as well as having an increased risk of infections and higher mortality. Human…
Charles Rudin MD, PhD of the Memorial Sloan Kettering Cancer Center, New York, NY discusses targeted therapies, immunotherapy and their combination in non-small cell lung cancer (NSCLC) therapy. Targeted therapy and immunotherapy are complimentary strategies. Targeted inhibitors are associated with very high response rate in tumors with specific mutations which are targeted by these drugs. However, almost all patients treated with targeted inhibitors will relapse. Immunotherapy is different in that are a smaller fraction of patients will respond, but response is potentially more durable. The goal of this trial was to try and get the benefits of each type of…
Beth Eaby-Sandy MSN, CRNP, OCN, of the Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA explains the different toxicities seen with immunotherapy compared to chemotherapy. Toxicities associated with immunotherapy are generally uncommon, but can be life threatening if they progress. It important for nurses to understand why these patients are having these toxicities, and how they differ from chemotherapy. Nurses must tell patients when to get in contact. Three of the most common severe immune-mediated toxicities from immunotherapies used in lung cancer are: pneumonitis, colitis, and rash/dermatitis. Pneumonitis and colitis are the two that can be life-threatening. Patients with pneumonitis…
Barbara Melosky, MD, FRCPC, of the University of British Columbia, Vancouver, BC discusses how the world of epidermal growth factor receptor (EGFR) mutating lung cancers has changed in terms of management, understanding, and the choices which are available. Research is investigating which patients might benefit from certain medications, as choice is expanding with each generation of drugs. There are first-generation EGFR tyrosine kinase inhibitors (TKIs); gefitinib, and erlotinib, second generation EGFR TKIs; afatinib, dacomitinib, and third generation; osimertinib. Dr Melosky is most excited about AURA3 data for osimertinib (NCT02151981). The choices today in the first-line setting for patients depend on…
Ales Ryska, MD, PhD, of the Charles University, Medical Faculty Hospital, Prague, Czech Republic gives an overview of a session he chaired, which focused on a multidisciplinary approach for the diagnosis of lung cancer. He explains how all specialties are required for correct diagnosis today, including endoscopists, pulmonologists, surgeons, pathologists, and molecular biologists. The first presentation was about the main challenges in the testing of lung cancer, covering what is currently available, and what prospects there are for the near future. His second presentation was about what is new with bronchoscopic techniques. Specifically, how endoscopy can get more material for…
At ASH 2016, MPN experts from across the nation share their perspective on what the future holds for MPNs, in both the short term and long term. Dr. John Mascarenhas from Mount Sinai School of Medicine in New York City, Dr. Catriona Jamieson of UC San Diego Health Moores Cancer Center, and Dr. Stephen T. Oh of Washington University School of Medicine provide an optimistic outlook on MPN research and treatment. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
It is an honor and a privilege to be selected to present at the American Society of Hematology Conference. Dr. Peter Voorhees is among the select few chosen due to the importance of her work over the past several years. In this video clip, Dr. Peter Voorhees talks about the importance of networking with multiple myeloma investigators at the conference.
It is an honor and a privilege to be selected to present at the American Society of Hematology Conference. Dr. Saad Usmani is among the select few chosen due to the importance of his work over the past several years. In this video clip, Dr. Saad Usmani talks about a unique immune profiling method that is transforming patient care.
It is an honor and a privilege to be selected to present at the American Society of Hematology Conference. Dr. Jonathan Gerber is among the select few chosen due to the importance of his work over the past several years. In this video clip, Dr. Jonathan Gerber talks about the significance of research collaboration from industry leaders across the country.
It is an honor and a privilege to be selected to present at the American Society of Hematology Conference. Dr. Belinda Avalos is among the select few chosen due to the importance of her work over the past several years. In this video clip, Dr. Avalos talks about the impact that LCI is making in research and treatment for blood cancers.
At ASH 2016, experts from across the nation discuss how genetic testing is affecting the evolution of treatment for MPNs. Dr. Stephen Oh of Washington University School of Medicine explains exactly what genetic testing could mean for patients. Dr. Catriona Jamieson of UC San Diego Health Moores Cancer Center follows by helping viewers to understand what the ongoing learnings reveal and the effect of looking at things at a “nano” level. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
We continue to provide informational videos for our Spanish speaking community and welcome Dr. Luis Raez, MD FACP FCCP, Chief of Hematology/Oncology and Medical Director at Memorial Cancer Institute, and Clinical Associate Professor of Medicine at Florida International University. Dr. Raez joined GRACE to discuss the basics of lung cancer. In this 27th video for the Spanish lung cancer video library, Dr. Raez discusses potential side effects of immune checkpoint inhibitors and basic management approaches.
In this presentation from Lymphoma & Myeloma 2016, Dr. Joseph R. Mikhael discusses the best induction therapy for transplant-eligible myeloma patients. Earn CME credit for a related activity at the following location: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7225 © 2016 Imedex, LLC.
In this presentation from Lymphoma & Myeloma 2016, Dr. Philippe Moreau argues that myeloma patients should receive maintenance therapy indefinitely after transplant. Earn CME credit for a related activity at the following location: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7225 © 2016 Imedex, LLC.
In this presentation from Lymphoma & Myeloma 2016, Dr. James R. Berenson argues for no or limited maintenance therapy in the post-transplant setting for myeloma. Earn CME credit for a related activity at the following location: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7225 © 2016 Imedex, LLC.
In this presentation from Lymphoma & Myeloma 2016, Dr. Kenneth C. Anderson discusses new paradigms and therapies in the treatment of relapsed/refractory myeloma, with an emphasis on small molecules and monoclonal antibodies. Earn CME credit for a related activity at the following location: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7225 © 2016 Imedex, LLC.
In this presentation from Lymphoma & Myeloma 2016, Dr. Maria-Victoria Mateos discusses how to assess who has smoldering myeloma and when to treat it. Earn CME credit for a related activity at the following location: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7225 © 2016 Imedex, LLC.
In this presentation from Lymphoma & Myeloma 2016, Dr. C. Ola Landgren provides an update on new approaches and the clinical value of assessing minimal residual disease in myeloma. Earn CME credit for a related activity at the following location: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7225 © 2016 Imedex, LLC.
In this presentation from Lymphoma & Myeloma 2016, Dr. Scott A. Ely elucidates a fresh look at myeloma proliferation. Earn CME credit for a related activity at the following location: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7225 © 2016 Imedex, LLC.
In this presentation from Lymphoma & Myeloma 2016, Dr. Raphael Fonseca discusses the challenges in defining an actionable approach to precision medicine in the treatment of myeloma. Earn CME credit for a related activity at the following location: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7225 © 2016 Imedex, LLC.
In this Key Insights activity, Drs. Corey J. Langer, MD and Joshua Bauml discuss the key take-home points from the 21st Annual Perspectives in Thoracic Oncology meeting held November 18-19, 2016 in New York. Earn CME credit for this activity at the following location: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7228 © 2016 Imedex, LLC.
At ASH 2016, MPN experts from around the nation came together to review current and developing therapies for MPNs. Dr. John Mascarenhas of Mount Sinai School of Medicine in New York City discussed the use of agents that are currently approved for other conditions as well as JAK inhibitors in development. Dr. Catriona Jamieson from UC San Diegos Moores Cancer Center explains the possibility of therapy tailored to each patient, while Dr. Stephen Oh from Washington University School of Medicine expands on telomerase inhibitors and anti-fibrotic medicines. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook…
Theodore S. Hong, MD of Massachusetts General Hospital talks about the Promising Results for Folfirinox with Losartan in Locally Advanced Pancreatic Cancer at ASCO GI 2017.
Theodore S. Hong, MD of Massachusetts General Hospital outlines a Phase II Study of Folfirinox followed my Individualized Radiation Therapy with Borderline Resectable Pancreatic Cancer at ASCO GI 2017.
Theodore S. Hong, MD of Massachusetts General Hospital outlines how Metformin may increase Overall Survival in Patients with Resectable Pancreatic Cancer at ASCO GI 2017.
Theodore S. Hong, MD of Massachusetts General Hospital discusses the Secondary Analysis of RTOG 9704 Gemcitabine versus 5-FU in Resectable Pancreatic Cancer at ASCO GI 2017
Theodore S. Hong, MD of Massachusetts General Hospital outlines how Novel Agents and Proton Beam Therapy studies may be on the horizon for Locally Recurrent Rectal Cancer at ASCO GI 2017.
Theodore S. Hong, MD of Massachusetts General Hospital says that a 2nd Opinion from Surgeon Helpful in the Management of Locally Recurrent Rectal Cancer at ASCO GI 2017
John L. Marshall of Lombardi Comprehensive Cancer Institute discusses how the results of the RESORCE Trial will impact treatment for HCC patients at the 2017 Gastrointestinal Cancers Symposium (Annual Meeting GI) in San Francisco, CA.
John L. Marshall, MD of Lombardi Comprehensive Cancer Center gives his perspective on how to choose molecular tests for treating newly diagnosed colorectal cancer patients at the 2017 Gastrointestinal Cancers Symposium (Annual Meeting GI) in San Francisco, CA.
John L. Marshall, MD of Lombardi Comprehensive Cancer Center gives his take on how to integrate genetic mutations, and left sided versus right sided CRC, into a treatment decision at the 2017 Gastrointestinal Cancers Symposium (Annual Meeting GI) in San Francisco, CA.
John L. Marshall MD, of Lombardi Comprehensive Cancer Center discusses how checkpoint inhibitors are being integrated into gastrointestinal cancers at the 2017 Gastrointestinal Cancers Symposium (Annual Meeting GI) in San Francisco, CA.
John L. Marshall of Lombardi Comprehensive Cancer Center discusses how vaccines can be used to broaden the use of immunotherapies in GI Cancer patients at the 2017 Gastrointestinal Cancers Symposium (Annual Meeting GI) in San Francisco, CA.
Philip Agop Philip, MD, PhD, FRCP of Karmanos Cancer Institute gives his perspective on considerations when treating a newly diagnosed patient with stage 4 pancreatic cancer at the 2017 Gastrointestinal Cancers Symposium (Annual Meeting GI) in San Francisco, CA.
Philip Agop Philip, MD, PhD, FRCP of Karmanos Cancer Institute gives his perspective on how to use both TAS-102 and regorafenib for patients with metastatic colorectal cancer at the 2017 Gastrointestinal Cancers Symposium (Annual Meeting GI) in San Francisco, CA.
Philip Agop Philip, MD, PhD, FRCP of Karmanos Cancer Institute discusses whether or not resected pancreatic cancer patients should be offered adjuvant therapy at the 2017 Gastrointestinal Cancers Symposium (Annual Meeting GI) in San Francisco, CA.
Philip Agop Philip, MD, PhD, FRCP of Karmanos Cancer Institute gives his take on choosing molecular tests for treatment for newly diagnosed Colorectal Cancer patients at the 2017 Gastrointestinal Cancers Symposium (Annual Meeting GI) in San Francisco, CA.
Philip Agop Philip, MD, PhD, FRCP of Karmanos Cancer Institute discusses how healthcare professionals are integrating immunotherapy in existing treatment regimens for patients with colorectal cancer at the 2017 Gastrointestinal Cancers Symposium (Annual Meeting GI) in San Francisco, CA.
Stevin Lin, MD, PhD of MD Anderson Cancer Center highlights how Proton Therapy May Have Benefits to Immunotherapy Treatments from ASCO GI 2017.
Stevin Lin, MD, PhD of MD Anderson Cancer Center discusses how using Proton therapy can lower Lymphopenia in esophageal cancer at ASCO GI 2017.
Stevin Lin, MD, PhD of MD Anderson Cancer Center outlines the next steps for research and clinical trials associated to Proton Therapy from ASCO GI 2017
Stevin Lin, MD, PhD of MD Anderson discusses the costs of Proton Therapy versus the cost of IMRT and 3d conformal at ASCO GI 2017.
Alan P. Venook, MD, FAnnual Meeting of Helen Diller Family Comprehensive Cancer Center discusses how the 80405 study in CRC patients impacted treatment guidelines at the 2017 Gastrointestinal Cancers Symposium (Annual Meeting GI) in San Francisco, CA.
Alan P. Venook, MD, FAnnual Meeting of Helen Diller Family Comprehensive Cancer Center gives his take on ordering which molecular tests when determining treatment approach for newly diagnosed patients with CRC at the 2017 Gastrointestinal Cancers Symposium (Annual Meeting GI) in San Francisco, CA.
Alan P. Venook, MD, FAnnual Meeting of Helen Diller Family Comprehensive Cancer Center gives his perspective on how to use both TAS-102 and regorafenib in patients with metastatic colorectal cancer at the 2017 Gastrointestinal Cancers Symposium (Annual Meeting GI) in San Francisco, CA.
Alan P. Venook, MD, FAnnual Meeting of Helen Diller Family Comprehensive Cancer Center talks of how he identifies subgroups of HCC patients that are more likely to respond to therapy at the 2017 Gastrointestinal Cancers Symposium (Annual Meeting GI) in San Francisco, CA.
Alan P. Venook, MD, FAnnual Meeting of Helen Diller Family Comprehensive Cancer Center discusses the date of the RESORCE Trial and how it changed the role of regorafenib in the treatment of unresectable HCC at the 2017 Gastrointestinal Cancers Symposium (Annual Meeting GI) in San Francisco, CA.
Alan P. Venook, MD, FAnnual Meeting of Helen Diller Family Comprehensive Cancer Center discusses how healthcare professionals are integrating immunotherapy into existing treatment regimens for patients with gastric cancer at the 2017 Gastrointestinal Cancers Symposium (Annual Meeting GI) in San Francisco, CA.
Alan P. Venook MD, FAnnual Meeting of Helen Diller Family Comprehensive Cancer Center discusses integrating immunotherapy into existing treatment regimens for patients with HCC at the 2017 Gastrointestinal Cancers Symposium (Annual Meeting GI) in San Francisco, CA.